Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 4/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19706246 | 0.90 | BRAF (0.37) | CNR2BRAFTSHRKDM1AMAOB | |
| SCHEMBL19706127 | 0.88 | TSHR (0.47) | CNR2TSHRGRM5ABL1TP53 | |
| SCHEMBL19365548 | 0.84 | TRPV3 (0.37) | KDM1ATRPV3ABL1CLK2 | |
| SCHEMBL19706131 | 0.82 | POLB (0.42) | CNR2BRAFTSHRFAAHKDM1A | |
| SCHEMBL19706147 | 0.82 | BRAF (0.44) | CNR2BRAFFAAHKDM1AFYN | |
| SCHEMBL19670657 | 0.80 | MPL (0.42) | CNR2FAAHKDM1AMAOBGRM5 | |
| SCHEMBL17618825 | 0.80 | ABL1 (0.35) | CNR2BRAFTSHRFAAHFYN | |
| SCHEMBL19670539 | 0.78 | BRAF (0.37) | CNR2BRAFKDM1AMAOBCNR1 | |
| SCHEMBL16776248 | 0.78 | GRM5 (0.38) | CNR2TSHRFAAHCNR1GRM5 | |
| SCHEMBL19706123 | 0.78 | ABL1 (0.39) | CNR2FYNGRM5ABL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CNR2 2514/4885BRAF 3419/4885TSHR 3064/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | CNR2 2514/4885BRAF 3419/4885TSHR 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.